Literature DB >> 21960691

Deriving valid population-based cancer survival estimates in the presence of nonnegligible proportions of cancers notified by death certificates only.

Hermann Brenner1, Bernd Holleczek.   

Abstract

BACKGROUND: Studies of cancer survival by population-based cancer registries are a key component in monitoring progress against cancer. Patients notified by death certificates only (DCO) are commonly excluded from such studies. The validity of this "exclude DCO" approach has been questioned and an alternative "correct for DCO" approach has been proposed.
METHODS: We assess the validity of both the "exclude DCO" approach and the "correct for DCO" approach using model calculations. We illustrate implications for population-based cancer survival analyses by analyses of 5-year relative survival of cancer patients in Saarland, Germany.
RESULTS: The "exclude DCO" approach provides (too) optimistic survival estimates and the "correct for DCO" approach provides (too) pessimistic survival estimates under plausible assumptions. For example, in case of true survival of 50%, underascertainment of 5% of surviving patients and of 15% of dying patients (yielding a proportion of DCO cases of 7.7%), the two approaches would provide survival rate estimates of 52.8% and 48.8%, respectively. The difference of survival estimates obtained with both approaches increases with incompleteness of registration and the proportion of DCO cases. Trace back of DCO cases shifts survival estimates from the former toward the latter estimate.
CONCLUSIONS: In case of nonnegligible DCO proportions, cancer survival studies should not be exclusively based on either the "exclude DCO" or the "correct for DCO" approach. A combination of estimates from both approaches may be useful to delineate a plausibility range for true survival. IMPACT: Our results may help to enhance validity and comparability of population-based cancer survival estimates.

Entities:  

Mesh:

Year:  2011        PMID: 21960691     DOI: 10.1158/1055-9965.EPI-11-0697

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  10 in total

1.  Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century.

Authors:  Janick Weberpals; Dianne Pulte; Lina Jansen; Sabine Luttmann; Bernd Holleczek; Alice Nennecke; Meike Ressing; Alexander Katalinic; Maximilian Merz; Hermann Brenner
Journal:  Haematologica       Date:  2017-03-09       Impact factor: 9.941

Review 2.  Critical Points for Interpreting Patients' Survival Rate Using Cancer Registries: A Literature Review.

Authors:  Ayako Okuyama; Akiko Shibata; Hiroshi Nishimoto
Journal:  J Epidemiol       Date:  2017-10-28       Impact factor: 3.211

3.  Survival of patients with oral cavity cancer in Germany.

Authors:  Stefan Listl; Lina Jansen; Albrecht Stenzinger; Kolja Freier; Katharina Emrich; Bernd Holleczek; Alexander Katalinic; Adam Gondos; Hermann Brenner
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

4.  Study populations for period analyses of cancer survival.

Authors:  L Jansen; T Hakulinen; H Brenner
Journal:  Br J Cancer       Date:  2013-01-29       Impact factor: 7.640

5.  Trends of population-based breast cancer survival in Germany and the US: decreasing discrepancies, but persistent survival gap of elderly patients in Germany.

Authors:  Bernd Holleczek; Hermann Brenner
Journal:  BMC Cancer       Date:  2012-07-28       Impact factor: 4.430

6.  Breast cancer survival in Germany: a population-based high resolution study from Saarland.

Authors:  Bernd Holleczek; Lina Jansen; Hermann Brenner
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

7.  Survival of adults with acute lymphoblastic leukemia in Germany and the United States.

Authors:  Dianne Pulte; Lina Jansen; Adam Gondos; Alexander Katalinic; Benjamin Barnes; Meike Ressing; Bernd Holleczek; Andrea Eberle; Hermann Brenner
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

8.  Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century.

Authors:  Dianne Pulte; Benjamin Barnes; Lina Jansen; Nora Eisemann; Katharina Emrich; Adam Gondos; Stefan Hentschel; Bernd Holleczek; Klaus Kraywinkel; Hermann Brenner
Journal:  J Hematol Oncol       Date:  2013-09-16       Impact factor: 17.388

9.  Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century.

Authors:  Dianne Pulte; Felipe A Castro; Lina Jansen; Sabine Luttmann; Bernd Holleczek; Alice Nennecke; Meike Ressing; Alexander Katalinic; Hermann Brenner
Journal:  J Hematol Oncol       Date:  2016-03-22       Impact factor: 17.388

10.  Future projection of the health and functional status of older people in Japan: A multistate transition microsimulation model with repeated cross-sectional data.

Authors:  Megumi Kasajima; Hideki Hashimoto; Sze-Chuan Suen; Brian Chen; Hawre Jalal; Karen Eggleston; Jay Bhattacharya
Journal:  Health Econ       Date:  2020-07-14       Impact factor: 2.395

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.